Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 2/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | PLK1 | P53350 | 1/20 | 0.36 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.36 |
| ▸ | MPO | P05164 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2115369 | 0.97 | POLB (0.40) | POLBZAP70CSF1RPDGFRBKDR | |
| SCHEMBL2114095 | 0.92 | POLB (0.41) | POLBZAP70CSF1RMPOHRH3 | |
| SCHEMBL2115041 | 0.91 | DHFR (0.40) | PDGFRBKDRPLK1PLK3MPO | |
| SCHEMBL2114966 | 0.88 | DHFR (0.41) | PDGFRBKDRPLK1PLK3MPO | |
| SCHEMBL2115239 | 0.87 | TAAR1 (0.40) | POLB | |
| SCHEMBL2113730 | 0.84 | NPC1 (0.49) | PDGFRBKDRPLK1PLK3 | |
| SCHEMBL2113341 | 0.83 | TAAR1 (0.40) | POLBPDGFRBKDRPLK1PLK3 | |
| SCHEMBL2114730 | 0.83 | DHFR (0.42) | PDGFRBKDRPLK1PLK3MPO | |
| SCHEMBL2112982 | 0.83 | JAK2 (0.35) | POLBPDGFRBKDRPLK1PLK3 | |
| SCHEMBL2114912 | 0.83 | KMT2A (0.44) | POLBPDGFRBKDRPLK1PLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158641-B2 | 2-anilino-4-aminoalkyleneaminopyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-17 | — | — | US | disclosed |
| US-20090181995-A1 | 2-ANILINO-4-AMINOALKYLENEAMINOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-16 | — | — | US | disclosed |
| EP-2032543-A1 | 2-ANILINO-4-AMINOALKYLENEAMINOPYRIMIDINES | Boehringer Ingelheim International GmbH (DE) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007146977-A1 | 2-ANILINO-4-AMINOALKYLENEAMINOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181995-A1 | 2-ANILINO-4-AMINOALKYLENEAMINOPYRIMIDINES | PRKCA, PRKCH, PRKCG | POLB 2589/4885ZAP70 254/4885CSF1R 4073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.